Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Prospective Antidementia Drug Improves Brain Function

By BiotechDaily International staff writers
Posted on 15 Oct 2012
A new antidementia drug candidate has been found to be highly active in creating new neuronal connections and improving the cognitive function of rats with Alzheimer’s-like mental impairment.

Researchers at Washington State University (WSU; Pullman, WA, USA) have developed a new compound, named Dihexa, designed to repair damage that has already occurred and thereby recover lost brain function. This is a significant departure from current treatments for diseases such as Alzheimer’s, treatments that only slow the process of cell death or inhibit the neurotransmitter cholinesterase. Also, the Pharmaceutical Research and Manufacturers of America (PhRMA) reported that only 3 of 104 possible treatments have been approved in the past 13 years, a 34 to 1 ratio of setbacks to successes.

Joe Harding, professor at the WSU College of Veterinary Medicine, Jay Wright, professor at the WSU College of Arts and Sciences, and other WSU colleagues, reported their findings on October 10, 2012, in the early online section of the Journal of Pharmacology and Experimental Therapeutics. Prof. Harding designed a smaller version of the peptide angiotensin IV. Unlike the original peptide and early candidate molecules based on it, the new analog, Dihexa, was found to be both stable and able to cross the blood-brain barrier. It can also move from the gut into the blood and so could be taken orally in pill form.

The WSU team tested Dihexa on several dozen rats treated with scopolamine. Typically, a rat treated with scopolamine will not learn the location of a submerged platform in a water tank, orienting with cues outside the tank. After receiving Dihexa, all rats learned the task whether receiving the drug orally, by injection, or directly into the brain. Similar results were observed where a smaller group of old rats performed like young rats after treatment; however, while these results were statistically valid, studies with larger test groups will be needed to check the finding.

The "gold standard” compound for creating neuronal connections is brain-derived neurotrophic factor (BDNF). In bench assays using living nerve cells to monitor new neuronal connections, Dihexa was seven orders of magnitude more powerful than BDNF, which itself has yet to be effectively developed for therapeutic use. "We quickly found out that this molecule was [very highly] active,” said Prof. Harding. These results further suggest that Dihexa or molecules like it may also have applications for other neurodegenerative diseases or brain traumas where neuronal connections are lost. Development of Dihexa for human use will begin after safety testing and US Food and Drug Administration approval is obtained for clinical trials.

Related Links:

Washington State University




Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.